Beyond Air Inc (XAIR)

Currency in USD
2.320
-0.130(-5.31%)
Closed·
2.3200.000(0.00%)
·
XAIR Scorecard
Full Analysis
Net income is expected to grow this year
XAIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.2902.400
52 wk Range
2.22513.522
Key Statistics
Prev. Close
2.32
Open
2.4
Day's Range
2.29-2.4
52 wk Range
2.225-13.522
Volume
229.77K
Average Volume (3m)
261.33K
1-Year Change
-71.01%
Book Value / Share
2.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XAIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.200
Upside
+382.76%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Beyond Air Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Beyond Air Inc Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air Inc SWOT Analysis


Innovative NO Delivery
Beyond Air's LungFit PH system generates nitric oxide from room air, potentially disrupting the $700 million global market for NO delivery systems
Financial Hurdles
Explore Beyond Air's strategy to overcome significant cash burn and reach cash flow breakeven by fiscal year 2027, despite lowered revenue projections
Market Expansion Plans
Learn about Beyond Air's efforts to expand LungFit PH's approved uses, including a pending FDA decision for cardiac surgeries and pursuit of CE mark in Europe
Competitive Landscape
Delve into Beyond Air's positioning against dominant players like Mallinckrodt, with analyst price target at $2.00 amid market challenges and opportunities
Read full SWOT analysis

Beyond Air Inc Earnings Call Summary for Q1/2026

  • Revenue surged 157% YoY to $1.8M, but EPS missed at -$1.53 vs -$0.10 forecast; stock up 3.8% premarket to $3.28
  • Net loss reduced to $7.7M from $12.2M; gross profit turned positive; operating expenses cut by 40%
  • FY2026 revenue guidance reaffirmed at $12-$16M; expects growth each quarter and momentum in FY2027
  • CEO confident in overcoming market barriers; CFO assures financial stability into 2026 with healthy liquidity
  • Analysts' price targets range $11-$40; company focuses on FDA approval for second-gen machine and international expansion
Last Updated: 12/08/2025, 22:26
Read Full Transcript

Compare XAIR to Peers and Sector

Metrics to compare
XAIR
Peers
Sector
Relationship
P/E Ratio
−0.3x−3.6x−0.5x
PEG Ratio
0.00−0.200.00
Price/Book
1.2x2.3x2.6x
Price / LTM Sales
2.5x3.5x3.3x
Upside (Analyst Target)
-11.8%40.6%
Fair Value Upside
Unlock11.4%5.3%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.200
(+382.76% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.53 / -0.10
Revenue / Forecast
1.76M / 2.06M
EPS Revisions
Last 90 days

XAIR Income Statement

People Also Watch

60.45
BMNR
-1.91%
17.810
ZETA
-3.42%
3.930
ONDS
+11.65%
3.040
OPEN
+25.62%
15.45
BULL
+2.86%

FAQ

What Stock Exchange Does Beyond Air Trade On?

Beyond Air is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Beyond Air?

The stock symbol for Beyond Air is "XAIR."

What Is the Beyond Air Market Cap?

As of today, Beyond Air market cap is 12.12M.

What Is Beyond Air's Earnings Per Share (TTM)?

The Beyond Air EPS (TTM) is -10.36.

When Is the Next Beyond Air Earnings Date?

Beyond Air will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is XAIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Beyond Air Stock Split?

Beyond Air has split 2 times.

How Many Employees Does Beyond Air Have?

Beyond Air has 61 employees.

What is the current trading status of Beyond Air (XAIR)?

As of 15 Aug 2025, Beyond Air (XAIR) is trading at a price of 2.32, with a previous close of 2.32. The stock has fluctuated within a day range of 2.29 to 2.40, while its 52-week range spans from 2.23 to 13.52.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.